Coherus BioSciences Announces Executive and Board Changes
Ticker: CHRS · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1512762
Sentiment: neutral
Topics: executive-change, board-change, management-transition
TL;DR
Coherus CEO Dennis Lanfear out, new execs and board members in. Big shakeup.
AI Summary
Coherus BioSciences, Inc. announced on May 31, 2024, changes in its executive team and board of directors. Specifically, Dennis M. Lanfear has departed as CEO and from the Board of Directors. The company has also appointed new officers and directors, including the election of new board members and the appointment of a new Chief Medical Officer.
Why It Matters
Significant leadership changes can signal shifts in company strategy, operational focus, or financial performance, impacting investor confidence and future prospects.
Risk Assessment
Risk Level: medium — Executive departures and board changes can introduce uncertainty regarding future strategy and leadership stability.
Key Numbers
- 001-36721 — SEC File Number (Identifier for Coherus BioSciences, Inc.)
- 27-3615821 — IRS Employer Identification Number (Tax identification for Coherus BioSciences, Inc.)
Key Players & Entities
- Coherus BioSciences, Inc. (company) — Registrant
- Dennis M. Lanfear (person) — Departing CEO and Board Member
- May 31, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Redwood City, CA (location) — Principal executive offices
FAQ
Who has departed from Coherus BioSciences, Inc. as of May 31, 2024?
Dennis M. Lanfear has departed as CEO and from the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is May 31, 2024.
In which state is Coherus BioSciences, Inc. incorporated?
Coherus BioSciences, Inc. is incorporated in Delaware.
What is the principal executive office address for Coherus BioSciences, Inc.?
The principal executive office is located at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065.
What type of report is this filing?
This filing is a Current Report on Form 8-K.
Filing Stats: 986 words · 4 min read · ~3 pages · Grade level 11 · Accepted 2024-06-05 09:11:23
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share CHRS The Nasdaq
- $60,000 — nd the Audit Committee in the amount of $60,000. On June 4, 2024, Ms. Karachun received
Filing Documents
- chrs-20240531x8k.htm (8-K) — 38KB
- 0001558370-24-008918.txt ( ) — 163KB
- chrs-20240531.xsd (EX-101.SCH) — 4KB
- chrs-20240531_def.xml (EX-101.DEF) — 3KB
- chrs-20240531_lab.xml (EX-101.LAB) — 16KB
- chrs-20240531_pre.xml (EX-101.PRE) — 10KB
- chrs-20240531x8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 5, 2024 COHERUS BIOSCIENCES, INC. By: /s/ Dennis M. Lanfear Name: Dennis M. Lanfear Title: Chief Executive Officer